Samsung Biologics
Samsung Biologics, a leading player in the biopharmaceutical industry, is headquartered in Incheon, South Korea (KR). Founded in 2011, the company has rapidly established itself as a key provider of contract development and manufacturing services (CDMO) for biopharmaceuticals, catering to a global clientele. With a focus on monoclonal antibodies and other biologics, Samsung Biologics offers unique solutions that leverage cutting-edge technology and state-of-the-art facilities. The company has achieved significant milestones, including the completion of its third manufacturing plant, which enhances its production capacity and reinforces its market position. Recognised for its commitment to quality and innovation, Samsung Biologics continues to set industry standards, making it a preferred partner for biopharmaceutical companies worldwide.
DitchCarbon Score
How does Samsung Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Samsung Biologics's score of 48 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Samsung Biologics's reported carbon emissions
In 2023, Samsung Biologics reported total carbon emissions of approximately 754,473,000 kg CO2e. This figure includes 528,480,000 kg CO2e from Scope 1 emissions, 155,522,000 kg CO2e from Scope 2 emissions, and 528,480,000 kg CO2e from Scope 3 emissions. This represents a significant reduction from 2022, when total emissions were about 961,800,000 kg CO2e, with Scope 1 at 55,716,000 kg CO2e, Scope 2 at 114,372,000 kg CO2e, and Scope 3 at 791,713,000 kg CO2e. Samsung Biologics has set ambitious climate commitments, aiming for net zero emissions by 2050 or earlier. The company plans to reduce direct emissions by 32% by 2030 and 62% by 2040, using 2022 as the baseline year. Additionally, it aims to cut suppliers' emissions by 36% by 2030 and 73% by 2040. The emissions data is not cascaded from any parent organization, and all figures are reported directly by Samsung Biologics Co., Ltd. The company is actively working towards its climate goals, demonstrating a commitment to sustainability in the biopharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 41,469,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
| Scope 2 | 84,993,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Samsung Biologics is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
